" In calendar 2H21 and 1H22, we look forward to Phase 1 results for PD1-Vaxx (determination of optimal
biological dose as monotherapy and combination therapy, respectively). In calendar 1H22 and 1H23, we look
forward to Phase 2 data for HER-Vaxx (PFS and OS, respectively). Initial Phase 1 results for CHECKvacc and
VAXinia are expected in calendar 2H22, all of which should serve as meaningful investment catalysts."
Roth just rated IMU a buy, page-24
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.8¢ | $382.1K | 7.853M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 8072405 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 668099 | 5 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |